Work

Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps8574

Authors: Luis G. Paz-Ares, Suresh Senan, David Planchard, Luhua Wang, Alicia Cheong, Marie Huong Nguyen, Ruta Slepetis, Everett E. Vokes

Institutions: Hospital Universitario 12 De Octubre, Amsterdam University Medical Centers, Institut Gustave Roussy, Fondation Gustave Roussy, Chinese Academy of Medical Sciences & Peking Union Medical College, Celgene (United States), University of Chicago Medical Center

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947385336

Cites:

Cited by: 2

Related to: 10